INVESTMENT REPORTS

British stock picks

Profiting from strategic resource needs

Aston Martin: 180-degree turn

28 February 2023

It's not the first time for me to write about Aston Martin Lagonda Global Holdings plc. When I last wrote about the company, I warned against investing into it.

This was just after the 2018 IPO, and what followed was the most disastrous performance of any high-profile IPO in the UK over the past five years. At one point, Aston Martin stock was down 97%!

Today, I am going to blow the horn for the company.

Aston Martin is one of the world's most iconic car brands, and it's currently also one of the most interesting investment cases on the London Stock Exchange.

Longer term, it may be one of those stocks that one shouldn't part with. Remember what happened to Ferrari since it went public in 2016?

A new life cycle for this death care company

Death care: a crisis-resistant industry

24 June 2022

On five out of seven days in mid-June 2022, over 90% of the stocks in the S&P 500 declined – the most overwhelming display of selling in history. There hasn't been a precedent for a sell-off of this nature since 1928.

Yet, the stock of one particular American company stood relatively firm.

Service Corporation International (ISIN US8175651046, NYSE:SCI) is the leading provider of funerals in the US. Even after the recent sell-off, its stock trades a mere 12% below its all-time high. Compared to ten years ago, it's up 500%. Over the past 20 years, it's up 34 times. Speak of a crisis-resistant investment!

The death care industry benefits from the only absolute certainty that we all have to live with: sooner or later, everyone becomes a customer.

At a time when tech, software and Internet investments have gone out of fashion, one particular death care company could come back into focus. Around the world, there are about a dozen publicly listed companies that provide funerals, cremations, and related services. I picked the one that is currently out of favour, but probably for not much longer.

The stock featured in this report should benefit from not one or two, but three catalysts during the remainder of 2022. The first one of these catalysts is due next month.

John Mnezies

John Menzies plc: British takeover target

13 August 2019

World-leading company (top 3 globally) John Menzies plc is virtually sure to get into the crosshairs of a takeover bid sometime during the next 12 months, possibly a lot earlier.

Its industry has high barriers of entry; it is projected to grow organically at nearly twice the speed of global GDP growth, and it offers a rare opportunity to consolidate a highly fragmented sector from the ground up. Large private equity companies are known to be interested in this space, but there is a real lack of suitable targets - except John Menzies plc!

Based on an estimate of its cash flow and a comparison with other recent transactions in the ground handling industry, the stock could attract a bid at a price that is 75% higher than the stock price at the time of publication.

Most recent

Sark – it’s not a big deal

Sark – it’s not a big deal

I had mobilised GBP 30m to buy a portfolio of real estate in Sark, with plans to IPO the company. How did it go, and what may happen next?

read more

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.